Cannabotech’s IntegrativePain products show 80% to 100% reduction in inflammatory pain

– The mouse model study was conducted by Cannabotech’s scientific team, led by Dr. Isaac Angel, pharmacologist specializing in drug development

– The products are based on a combination of mushrooms and cannabinoids that have achieved a strong therapeutic effect using low concentrations of THC

– Treatment expected to launch in Israel, US and UK in H2 2022

HERZLIYA, Israel, February 28, 2022 /PRNewswire/ — Cannabotech, a biomedical company that develops medical products based on cannabis and fungal extracts, has reported the results of a study which shows that the use of mushroom compounds in conjunction with cannabinoids results in 80% to 100% reduction in pain sensation.

Additionally, the addition of defined concentrations of other cannabinoids allowed the use of lower concentrations of THC to achieve very high medical efficacy.

Treatment should be started in Israel, in the United States and the United Kingdom during the second half of 2022 and will be integrated as part of Cannabotech’s concept of integrative oncology solutions, with existing therapeutic protocols. This would coincide with conventional chemotherapy while providing supporting scientific information to physicians.

Currently, approximately 50% to 80% of cancer patients receive additional integrative treatment in addition to chemotherapy (mainly herbal products, including cannabis). The main reasons for using integrative products include strengthening the immune system, improving treatment efficacy and reducing adverse events.[1],[2]

The Inflammatory Pain Mouse Model Study examined the effectiveness of IntegrativePain products designed to reduce pain, including those stemming from an inflammatory source such as arthritis, back pain, or side effects of chemotherapy .

The results clearly showed that adding cannabinoids to THC and CBD significantly increases medical efficacy. The uniqueness of the products lies in its ability to achieve high efficacy with high low THC/CBD concentrations combined with defined concentrations of other cannabinoids like THCV and CBG built to achieve maximum medical efficacy, without the “high “undesirable. Moreover, the results showed a significant decrease in pain intensity independent of a direct decrease in inflammatory amplitude, suggesting that the products immediately affect pain mechanisms in addition to their anti-inflammatory activity.

In addition, the fungal composition, consisting of seven different mushroom extracts, achieved very high efficacy on its own, as did the cannabinoids, with impressive pain relief results on their own. As the company expected, the mushroom and cannabinoid combined achieved a stronger effect than each individually. This finding supports Cannabotech’s claim that treating the endocannabinoid system (using cannabinoids) in conjunction with other systems, such as the immune system (using mushrooms), achieves a medical effect. increased and more powerful than each of these components individually.

The experience also highlighted the importance of tailoring treatment, with Cannabotech developing three pain treatment formulas: one for pain of inflammatory origin; another for pain of neuropathic origin; and a third for pain from integrated sources. Indeed, this experiment demonstrated the effectiveness of different products on inflammation and pain emanating from inflammatory sources, as well as variations in effectiveness between products when it comes to reducing pain from an inflammatory source. , as tested in the study. Cannabotech is currently developing a personalization system to provide physicians with the information needed to help them make informed, personalized decisions using IntegrativePain products.

IntegrativePain products are part of Cannabotech’s series of Integrative Oncology products designed to treat cancer patients and the side effects of chemotherapy. The trial is part of a series of studies conducted by Cannabotech on all integrative oncology products, which should be completed within a few months.

Cannabotech CEO Shaken Elhanan noted: “This is an important step in Cannabotech’s growth to become a leader in integrative oncology medicine. The integrative products developed by Cannabotech are intended for use in conjunction with chemotherapy treatment in multiple cancers, and are part of the company’s goal to set a new standard for the medical cannabis industry.

“Pain is the main indication among users of medical cannabis. However, while most products on the market are cannabis based on inflorescences with high concentrations of THC, Cannabotech presents a different concept, based on oil rich in other active ingredients, whose unique composition shows exceptional results without the unwanted side effects.”

dr. isaac angelpharmacological consultant of Cannabotech, said: “Pain is one of the central problems that the healthcare industry has been trying to solve for decades. life. Cannabotech’s products have shown increased efficacy in the current mouse model. We are encouraged by these results, which are another important step in proving the scientific feasibility of the products. We will continue to work to provide a cure for patients.

About Cannabotech:

Cannabotech is an Israeli biomedical company that develops botanical solutions for preventive medicine and integrative oncology medicine. These solutions are based on combinations of active agents from the cannabis plant and fungi that act on two central systems of the human body: the endocannabinoid system and the immune system.

Under the concept of integrative medicine, over the past two years Cannabotech has developed a series of 8 preparations designed to help patients with cancer and chronic pain, based on unique combinations of plants from medical cannabis and mushroom products. Upon completion of their development, the company’s goal is to designate the products to be integrated into the existing treatment protocol for oncology patients..

In parallel, Cannabotech is working on the development of a defined treatment protocol available to doctors and a technology for personalizing treatment.



Show original content:


Comments are closed.